|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
|
|
|
|
€ 1 600,00 |
Editeur
: |
ZZZ - Biovista |
Langue
: |
Anglais |
Date de publication : |
Juillet 2001 |
Taille du document : |
N/A |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (1) |
|
|
|
| 53 pages | Janvier 2007 | Anglais
|
|
|
| Main
focus: |
bioinformatics,genomics,human genome,biotechnology,...,...
|
| Research
focus: |
market size and estimates,market definition, |
| Geographic
focus: |
usa,singapore,united kingdom,australia |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pharmacogenomics 160 pages | Décembre 2000 |
The Human Genome Project and numerous corporate and academic human gene sequencing efforts have revealed, among others, that genes exist in the population in numerous mutated forms, some of which |
1 400,00 €
|
| |
| |
The Genomics Outlook To 2005: Transforming pharmaceutical and diagnostic markets 150 pages | Janvier 2002 |
Genomics is quietly transforming the pharmaceutical industry. Companies are moving from medicinal chemistry based drug discovery and development, to using information provided by genomics. V |
953,48 €
|
| |
| |
05-001: Improving Sales Rep Performance: A Global Analysis 219 pages | Janvier 2005 |
This report is designed to offer insights on how sales executives can align their sales force organization, recruitment and training in a way that reflects the needs and expectations of scientific cus |
1 520,00 €
|
| |
| |
Bioinformatics 150 pages | Décembre 2000 |
Automation has assaulted several levels of biological research generating vast amounts of data. Great leaps in DNA sequencing technology and automation led to a dramatic increase in sequence th |
1 400,00 €
|
| |
| |
03-054: Immunohistochemistry Market Benchmarking Survey 90 pages | Octobre 2003 |
This report provides an overview of the most commonly used methods and products for tissue/sample preparation and antigen detection to help suppliers understand researchers’ experiences, preferences a |
680,00 €
|
| |
| |
Combinatorics 150 pages | Décembre 2000 |
Identified by The Economist (*) as the industry to watch for 1997 in the chemicals sector, Combinatorics (also known as combinatorial chemistry) is an emerging platform technology that uses test t |
1 400,00 €
|
| |
| |
DNA Sequencing and PCR Markets 252 pages | Novembre 2004 |
The focus of this report is to describe the specific segment of the life sciences market called DNA sequencing. This analysis includes all of the generally accepted DNA-oriented analytical activiti |
2 800,00 €
|
| |
| |
03-019: The Market for Microbial Genotyping Products: Research and Testing Applications 183 pages | Juin 2003 |
The report identifies the kits, reagents and instrumentation that are most commonly used for microbial identification and analysis in both the research and testing arenas |
800,00 €
|
| |
| |
Biogenerics: Challenges and Promise 154 pages | Janvier 2005 |
Biogenerics: Challenges and Promise takes an insightful look at the burgeoning biogenerics industry and helps to clarify the complicated regulations that currently govern biogeneric development in bot |
799,20 €
|
| |
| |
Carbohydrate Therapeutics IRCD pages | Juillet 2001 |
Carbohydrates are the only class of biological molecule (there are four main classes: nucleic acids, proteins, lipids, and carbohydrates - commonly known as sugars), that can be found in direct associ |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
|
|
There is little doubt that biology is going large-scale. Great leaps in high throughput   technologies fueled by the genome sequencing projects, gene expression analysis   and proteomics, to name but a few, have resulted in a veritable explosion in the   amount of biological data that is generated, literally, on a daily basis. Bioinformatics   is the discipline of biology that has evolved to gather, store and manage in specialized   databanks the vast amounts of biological data, which it then mines for knowledge.   Together with the internet explosion, bioinformatics is revolutionizing the way   biological research is carried out today.  
In the post-genomic era, bioinformatics has become a fast-paced reality that   few can afford to ignore. Not surprisingly, practitioners are increasingly using   bioinformatics tools and approaches in a wide spectrum of drug discovery and   development tasks in an effort to understand basic biological and disease mechanisms,   identify new targets and to select and design novel candidates that will lead   to effective therapies.  
The power of bioinformatics is such that new players are entering the field   from many related fields: biomedicine, biotechnology, information technology   and instrumentation. Each brings a unique angle to a very complex problem and   as a result there is increased collaboration and technology fusion in an effort   to accelerate and make more efficient the highly competitive discovery and development   process. This has created a new breed of companies that are becoming increasingly   visible and sought after in the biotech world.  
But what is bioinformatics and how can a company best come to grips with it?   Pick up this report and you will find out:  
* What is bioinformatics and why it has risen to such prominence
  * What are the important tools and techniques used in bioinformatics
  * What are the major databases and how they are organized
  * Where can bioinformatics be used effectively in the drug development process
  * Who are the leading companies and what kinds of business collaborations they   are pursuing
  * What are the major issues concerning bioinformatics, its present and future   applications  
This Biovista Industry Review aims to be used as a guide and a tool by the   practitioners who are considering bioinformatics either as a business opportunity   or as a source of critical technologies for their organization.
|
|
1. INTRODUCTION
2. APPROACHES AND TOOLS
3. DATABASES
4. BIOINFORMATICS IN DRUG DISCOVERY AND DISEASE
5. INDUSTRY REPRESENTATIVE PROFILES
6. BIOINFORMATICS COMPANIES
7. BIOINFORMATICS PATENTS
8. THE FUTURE OF BIOINFORMATICS
9. REFERENCES AND FURTHER READING
APPENDICES
|
|
|
PPLSEN
|
|
|
|
|